Gepotidacin治疗尿路感染的安全性与疗效:GRADE系统评价与荟萃分析
该研究汇总三项III期随机对照试验共3510例女性急性非复杂性尿路感染患者,比较Gepotidacin与呋喃妥因的疗效与安全性。结果显示Gepotidacin复合治疗成功率和微生物清除率均优于呋喃妥因,但胃肠道不良事件(腹泻、恶心)更常见,严重不良事件罕见且组间相似。
要点
- Gepotidacin复合治疗成功率和微生物清除率均优于呋喃妥因。
- 腹泻和恶心等胃肠道不良事件在Gepotidacin组更频繁。
- 严重不良事件罕见且两组相似,需关注长期耐受性与耐药监测。
核心结论
- 对女性急性非复杂性尿路感染,Gepotidacin在复合结局和微生物学结局上优于呋喃妥因,但轻度至中度胃肠道毒性增加。
研究设计与样本
- PRISMA合规的系统评价与随机效应荟萃分析,纳入三项III期随机对照试验(EAGLE-2、EAGLE-3、EAGLE-J),共3510例参与者(Gepotidacin 1853例,呋喃妥因1657例),采用RoB 2评估偏倚风险,GRADE评级证据确定性。
主要发现
- Gepotidacin较呋喃妥因提高复合治疗成功率(RR 1.20;95%CI 1.10-1.31;I2=0%;P<0.001)。
- Gepotidacin改善微生物学清除(RR 1.14;95%CI 1.07-1.21;I2=2%;P<0.001)。
- 胃肠道不良事件在Gepotidacin组更常见:腹泻RR 5.51(95%CI 4.08-7.45),恶心RR 2.49(95%CI 1.56-3.97)。
- 严重不良事件罕见且两组相似。
临床怎么用
- 对女性急性非复杂性尿路感染,Gepotidacin可作为呋喃妥因之外的口服治疗选择,但需权衡其胃肠道不良反应风险。
局限性
- 证据仅来自三项III期随机对照试验,长期耐受性与耐药性数据有限,作者建议开展长期耐受性和耐药监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial resistance threatens oral treatment options for acute uncomplicated urinary tract infection (uUTI). Gepotidacin (Blujepa) is a novel oral triazaacenaphthylene antibiotic evaluated in Phase 3 trials versus nitrofurantoin. OBJECTIVES: To pool Phase 3 randomized evidence comparing gepotidacin and nitrofurantoin for efficacy and safety in female uUTI. METHODS: PRISMA-compliant systematic review and random-effects meta-analysis of Phase 3 randomized controlled trials. Two investigators independently screened records (using Rayyan), extracted data and assessed risk of bias with RoB 2; certainty was rated with GRADE. Outcomes were pooled as risk ratios (RR) or mean differences with 95% confidence intervals (CI) using RevMan 5.4. RESULTS: Three trials (EAGLE-2, EAGLE-3 and EAGLE-J) including 3510 participants (gepotidacin n = 1853; nitrofurantoin n = 1657) were included. Gepotidacin increased composite therapeutic success versus nitrofurantoin (RR 1.20; 95% CI 1.10-1.31; I2 = 0%; P < 0.001) and improved microbiological eradication (RR 1.14; 95% CI 1.07-1.21; I2 = 2%; P < 0.001). Gastrointestinal adverse events were more frequent with gepotidacin (diarrhoea RR 5.51; 95% CI 4.08-7.45; nausea RR 2.49; 95% CI 1.56-3.97). Serious adverse events were rare and similar between groups. Certainty of evidence per outcome is presented in Table S2 (available as Supplementary data at JAC Online). CONCLUSIONS: Gepotidacin provides superior composite and microbiological outcomes relative to nitrofurantoin for female uUTI but is associated with increased mild-to-moderate gastrointestinal toxicity. Long-term tolerability and resistance surveillance are recommended.
引用
- Ibrahim T, Burhan M, Naveed MA, et al. Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis. J Antimicrob Chemother. 2026. PMID: 41549666. doi:10.1093/jac/dkaf469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。